Actively Recruiting

Phase Not Applicable
Age: 20Years - 80Years
FEMALE
NCT05478876

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

Led by CNAO National Center of Oncological Hadrontherapy · Updated on 2024-08-21

9

Participants Needed

1

Research Sites

364 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free survival (PFS) and local control (LC) in patients diagnosed with mucosal melanoma of lower genital tract. Systemic treatment with immunotherapy is not the subject of this study but is allowed both in the neoadjuvant and sequential regimens. Melanomas have always been considered poorly radiosensitive. It is now accepted that high LET (Linear Energy Transfer) particle beams, such as carbon ions, can offer a biological advantage, compared to photons treatment, in radio-resistant neoplasms treatment, thanks to their higher biological efficacy (RBE) against tumours with a low α/ ß ratio. In addition, carbon ions have the physical advantage of an inverted depth deposition profile compared to photons, allowing then a steep dose gradients that ensure increased sparing of adjacent healthy organs at risk (OARs).

CONDITIONS

Official Title

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

Who Can Participate

Age: 20Years - 80Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological diagnosis of mucosal melanoma
  • No extension of melanoma to the skin
  • Lymph node involvement only if limited to groin and pelvis
  • Age between 20 and 80 years
  • ECOG performance status of 0 to 2
  • No evidence of metastasis
  • Tumor at least 5 mm away from rectum and bladder wall
  • No previous radiotherapy
  • Written informed consent provided
  • Ability to understand the clinical trial's characteristics and consequences
  • Molecular tumor characterization and mutational status available
  • Disease staging completed with baseline exams
Not Eligible

You will not qualify if you...

  • Presence of hip prosthesis, metal prostheses, or any condition preventing proper imaging for treatment planning
  • Psychiatric or other disorders preventing informed consent
  • Previous invasive tumor unless disease-free for at least 3 years
  • Contraindication to MRI
  • Current pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CNAO

Pavia, Italy, 27100

Actively Recruiting

Loading map...

Research Team

A

Amelia Barcellini, MD

CONTACT

C

Cristina Bono, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here